Neurocrine Biosciences Announces the Appointment Of Lawrence Steinman, M.D. to Its Board of Directors
SAN DIEGO, Jan. 31 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has elected Lawrence Steinman, M.D. to its Board of Directors effective January 10, 2001. Dr. Steinman is Professor in the Department of Neurology and Neurological Sciences, Pediatrics and Genetics, Stanford University, School of Medicine.
"As one of the leading medical researchers in the fields of neurology and immunology, we are pleased to welcome Dr. Steinman to Neurocrine's Board of Directors," said Gary Lyons, President and Chief Executive Officer. "With five compounds in clinical development, we believe Dr. Steinman's extensive experience in Neurocrine's area of focus, will prove to be a valuable asset to our Board of Directors. I look forward to continue working with such an accomplished scientific leader."
Larry Steinman, one of Neurocrine's academic co-founders received his M.D. from Harvard University in 1973 and has served more than 20 years at Stanford University, School of Medicine, as a Professor of Neurology and Pediatrics, as well as serving as Professor of Immunology at the Weizmann Institute. Dr. Steinman became Chief Scientist, Neuroimmunology and a member of Neurocrine's Founding Board of Scientific and Medical Advisors and its Executive Committee in September 1992. He has been honored with the Weir Mitchell Award of the American Academy of Neurology and the Senator Jacob Javits Neuroscience Investigators Award from the United States Congress as well as The Dr. Friedrich Sasse Award for Outstanding Contributions in Immunology from the Free University of Berlin. He is Board Certified with the American Board of Psychiatry and Neurology and holds seven different patents in the United States, Europe and Australia.
Neurocrine Biosciences is a leading neuroscience company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The Company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.
Neurocrine Biosciences, Inc. news releases are also available through the Company's website via the Internet at http://www.neurocrine.com.
In addition to historical facts, this press release contains
forward-looking statements that involve a number of risks and uncertainties.
A more complete description of these risks can be found in the Company's Form
10K for the year ended December 31, 2000 and the current form 10Q each of
which should be read before making any investment in Neurocrine common stock.
Neurocrine undertakes no obligation to update the statements contained in this
press release after the date hereof.
SOURCE Neurocrine Biosciences, Inc.
Web site: http: //www.neurocrine.com
Company News On-Call: http: //www.prnewswire.com/comp/604138.html or fax, 800-758-5804, ext. 604138
CONTACT: Claudia Jones or Paul Hawran of Neurocrine Biosciences, 858-658-7600